
ChatGPTã§å ç§å°éå»ãµããªãŒãæªãäŸããè¯ãäŸã«ãªããææŠããŠã¿ã
æ¥æ¬å ç§åŠäŒã®ç æŽèŠçŽãäœæãµã³ãã«ããå ¬è¡šãããŠãããè¯ãäŸãšæªãäŸããããããŠããŸãã
ããã³ãããäœæãç¡æã§ã§ããã»ããããã®ã§GPT3.5ã§æ€èšãGPT4ã詊ããŸããã
ç®æš
å ç§åŠäŒã®ãµããªã®æªãäŸãè¯ãäŸã«ãªãããã³ãããäœã
现ããç®æš
ãµããªãŒã¯æžç¹æ¹åŒã®è©äŸ¡ã倧ããã®ã§äœè£ãéèŠã§ã以äžã®ãã€ã³ããããããŸããã
誀åè±åãè¡šèšæºãããªãã
æ€æ»å€ã®æ°åãšåäœåã®åè§ã¹ããŒã¹
å¥èªç¹âã«ã³ããšããªãªãã®çµ±äž
èå¯ã¯ã²ãšãŸããã¬ã€ãã©ã€ã³ãšã¬ã€ãã©ã€ã³ã«æžããŠããåèåŒçšã®ã¿ãããªãã
éœæ§æèŠãšé°æ§æèŠã¯çäŸã®å žåçãªãã®ãã«ããŒãã
以äžã¯
æ¥æ¬å
ç§åŠäŒãç
æŽèŠçŽäœæãšè©äŸ¡ã®æåŒãã
POSïŒProblem Oriented SystemïŒæ¹åŒã®ç æŽèŠçŽãäœæãã
ãã®å 容ã端çã«è¡šããã¿ã€ãã«ãèšèŒããïŒ
äŸïŒ ãããããšçºäœæ§ã®è¡é¢ç¯çããæ³èµ·ã§ããééåãã«ãã¢ã®äžäŸ
確å®èšºæåã«ã€ããŠ
âç¥èªã¯çšããªãïŒ
âå ¥é¢äžïŒãããã¯å€æ¥éé¢äžïŒã®éç床ã»éèŠæ§ã«åŸããäž»ç åã1
ã«èšèŒããïŒ
â2以äžã«å¯ç åãå䜵çãäž»èŠãªãã®ã«éãèšèŒããïŒ
ç æŽã«ã€ããŠ
âäž»ç åã«ã€ããŠèšèŒããïŒ
âãã®ä»ã®äž»ã»å¯ç åãå䜵çãªã©ãã¹ãŠã®ç æ°ã®çµç·¯ãç°¡æœã«èšåã
ãïŒ
âæ¢åŸæŽãå®¶ææŽãçæŽ»æŽçã¯å šãŠãèšèŒããå¿ èŠã¯ãªãïŒ
âãããã£ãŒã«ãè·æ¥ãéèŠãªå Žåã¯èšèŒããïŒ
å ¥é¢æçŸçïŒå€æ¥èšºå¯æçŸçïŒ
äžå¿ èŠãªãã®ã¯æžãããŠãèŠé ãããŸãšããïŒ
ãããã¬ã ãªã¹ã
ãããã¬ã ãªã¹ãã«æãããããããã¬ã ãšã¯ã蚺æåã§ã¯ãªãæ£
è ã蚺å¯ããŠããäžã§åé¡ãšãªãé ç®ã®ãªã¹ãã§ããïŒ
åŸã£ãŠãå蚺æã«åŸããããå蚺ã§ã®åé¡ç¹ãèšåºçç¶ãèšºå¯æ
èŠãæ€æ»å€ã®ç°åžžãªã©ãããªã¹ãã¢ãããããã¹ããã®ã§ããïŒ
å ¥é¢åŸçµéïŒå€æ¥èšºçäžã®çµéïŒãšèå¯
ç¹æ®æ€æ»çãå«ã蚺æãšãã®æ ¹æ ãæ²»çãšãã®ãšããã³ã¹ããã³è»¢åž°
ã«ã€ããŠèšèŒããïŒ
èå¯ã¯äž»ç åãäžå¿ã«ãã®éç床ã蚺æããã³æ²»çæ³éžæã«ããã劥
åœæ§ãç°¡æœã«è°è«ããïŒ
â»ãå ¥é¢åŸçµéããšãèå¯ãã¯ããããããããã¬ã ãç 忝ã«ç¬ç«ã
ãŠèšèŒãããããããã¯äœµããŠèšèŒãããããããã®æ§åŒã§ãæ§ããª
ãïŒ
â» å€ç§ç޹ä»çäŸã«ã€ããŠã¯æè¡æèŠãå«ããŠèå¯ããããšïŒãŸãã忀
çäŸã«ã€ããŠã¯åæ€æèŠãå«ããŠèå¯ããããš
ç·åèå¯ãäž»ç åãäžå¿ã«ãã®éç床ãå¯ç åãšã®é¢é£ã«ã€ããŠèšå
蚺æããã»ã¹ã¯é©åã
çŸç æŽã«é¢ããèŽåã¯é°æ§æèŠãå«ããŠååèšèŒãããŠãããïŒ
çµéïŒèº«äœèšºå¯ã®èšèŒã¯å åã§ãããïŒ
蚺æã«å¿ èŠãªæ€æ»ã®èšèŒã¯å åã§ãããïŒ
蚺æã«å¿ èŠãªç»åæèŠã®èšèŒã¯å åã§ããã
éå¥èšºæã«ã€ããŠã¯ååèšèŒãããŠããã
æ²»çæ³ã¯é©åã
äž»ç åã®æ²»çã«ã€ããŠèšèŒãå åã§ãããïŒ
å«ççåŠ¥åœæ§ïŒå«ççé æ ®ïŒ
æ£è ãå šäººçèŠéã§èšºçããŠãããïŒ
以äžã®ããã«èŠä»¶ãå
¬è¡šãããŠããŸãã®ã§ããããã¯ãªã¢ããã°è¯ããšããããšã«ãªããŸãã
ããã³ããã®äœæŠ
ChatGPTã®å ŽåãããŒã¯ã³ã®å¶éãããã®ã§å
šãŠããé¡ãããã«ã¯ãšã©ãŒãçããããããæ®µéçã«æ»ããŸãã
æ€æ»æèŠãæ°å€ãšåäœã¯åè§ã¹ããŒã¹ãããããåäœã®ããšã¯ã«ã³ããæåŸã®åäœã¯ããªãªãã«ããã
æ ¡æ£äœæ¥
æ€æ»å€ãšåäœã®èª¿æŽãæžç¹ãã€ã³ãã«ãªããšããã§ãã®ã§ã¯ãªã¢ããŠãããŸããåŠäŒã®ãµã³ãã«ããŒã¿ãåè§ã¹ããŒã¹ãã«ã³ããå ¥ãå¿ãããšããèšå®ã«å€ããŠããŸãã
è¡æ¶²æèŠïŒèµ€è¡ç494äž/ÎŒLHb16g/dLïŒHt47ïŒ
ïŒçœè¡ç6,700/ÎŒLïŒ
è¡å°æ¿22äž/ÎŒLïŒè¡æ¶²çååŠæèŠïŒTP 6.5 g/dLïŒç·ããªã«ãã³ 0.89 mg/dLïŒAST 26
U/LïŒALT36U/LïŒLD233U/L γ-GT120U/LïŒBUN17.4mg/dLãCr1.1mg/dLïŒ
å°¿é
ž7.2mg/dL è¡ç³ 104 mg/dLãHbA1c 5.3ïŒ
ïŒç·ã³ã¬ã¹ãããŒã« 219 mg/dL ããª
ã°ãªã»ãªã262mg/dLïŒNa145mEq/LïŒK4.2mEq/LïŒCl106mEq/LïŒBNP650pg/
mLïŒCRP0.22mg/dLïŒ
ããã³ãã
以äžã®æ€æ»æèŠãæ ¡æ£ããŠãã ãããæ°å€ åäœ,ããšããããã«äžŠãã§ããŸããæ°å€ã®ååŸã«åè§ã¹ããŒã¹ããããŠãã ãããç¶ããŠãåäœã®ããšã«,ããããŠãã ãããæåŸã®åäœã«ããªãªãããããŠäžããããè¡æ¶²æèŠïŒèµ€è¡ç 494äž/ÎŒLïŒHb 16 g/dLïŒHt 47ïŒ
ïŒçœè¡ç 6,700/ÎŒLïŒ
è¡å°æ¿ 22äž/ÎŒLïŒè¡æ¶²çååŠæèŠïŒTP 6.5 g/dLïŒç·ããªã«ãã³ 0.89 mg/dLïŒAST 26
U/LïŒALT 36 U/LïŒLD 233 U/LïŒÎ³-GT 120 U/LïŒBUN 17.4 mg/dLïŒCr 1.1 mg/dLïŒ
å°¿é
ž 7.2 mg/dLïŒè¡ç³ 104 mg/dLïŒHbA1c 5.3ïŒ
ïŒç·ã³ã¬ã¹ãããŒã« 219 mg/dLïŒããª
ã°ãªã»ãªã 262 mg/dLïŒNa 145 mEq/LïŒK 4.2 mEq/LïŒCl 106 mEq/LïŒ BNP 650 pg/
mLïŒ CRP 0.22 mg/dLïŒChatGPTã®çµæ
è¡æ¶²æèŠïŒèµ€è¡ç 494 äž/ÎŒL, Hb 16 g/dL, Ht 47 ïŒ
, çœè¡ç 6,700/ÎŒL, è¡å°æ¿ 22 äž/ÎŒLïŒ
è¡æ¶²çååŠæèŠïŒTP 6.5 g/dL, ç·ããªã«ãã³ 0.89 mg/dL, AST 26 U/L, ALT 36 U/L, LD 233 U/L, γ-GT 120 U/L, BUN 17.4 mg/dL, Cr 1.1 mg/dL, å°¿é
ž 7.2 mg/dL, è¡ç³ 104 mg/dL, HbA1c 5.3 ïŒ
, ç·ã³ã¬ã¹ãããŒã« 219 mg/dL, ããªã°ãªã»ãªã 262 mg/dL, Na 145 mEq/L, K 4.2 mEq/L, Cl 106 mEq/L, BNP 650 pg/mL, CRP 0.22 mg/dLïŒã ãããOKã§ãããèµ€è¡çãçœè¡çãè¡å°æ¿ã¯æ°å€ãšïŒÂµlã«ã¹ããŒã¹ãã€ããªãã®ã§æã§ã¹ããŒã¹ãæ¶ããŠãªãããŠãã ããããããã¯ãã³ãã¬ãŒãã䜿ãããWordãããã¹ããšãã£ã¿ã®æ ¡æ£ã䜿ããªã©ãã£ãŠãããšè¯ãã§ãã
ãµããªãããã³ããã§äœã
å ç§åŠäŒã®ç æŽèŠçŽã®æåŒãã«æºãããµããªãŒãã§ããããã«ããã³ãããå ¥åããŸã
å
ç§ãµããªãŒã®äœæãæäŒã£ãŠäžãããã«ãŒã«ã¯ä»¥äžã«ãªããŸããPOSïŒProblem Oriented SystemïŒæ¹åŒã®ç
æŽèŠçŽãäœæãããã®å
容ã端çã«è¡šããã¿ã€ãã«ãèšèŒããïŒäŸïŒ ãããããšçºäœæ§ã®è¡é¢ç¯çããæ³èµ·ã§ããééåãã«ãã¢ã®äžäŸç¢ºå®èšºæåã«ã€ããŠâç¥èªã¯çšããªãïŒâå
¥é¢äžïŒãããã¯å€æ¥éé¢äžïŒã®éç床ã»éèŠæ§ã«åŸããäž»ç
åã1ã«èšèŒããïŒâ2以äžã«å¯ç
åãå䜵çãäž»èŠãªãã®ã«éãèšèŒããïŒç
æŽã«ã€ããŠâäž»ç
åã«ã€ããŠèšèŒããïŒâãã®ä»ã®äž»ã»å¯ç
åãå䜵çãªã©ãã¹ãŠã®ç
æ°ã®çµç·¯ãç°¡æœã«èšåããïŒâæ¢åŸæŽãå®¶ææŽãçæŽ»æŽçã¯å
šãŠãèšèŒããå¿
èŠã¯ãªãïŒâãããã£ãŒã«ãè·æ¥ãéèŠãªå Žåã¯èšèŒããïŒå
¥é¢æçŸçïŒå€æ¥èšºå¯æçŸçïŒäžå¿
èŠãªãã®ã¯æžãããŠãèŠé ãããŸãšããïŒãããã¬ã ãªã¹ããããã¬ã ãªã¹ãã«æãããããããã¬ã ãšã¯ã蚺æåã§ã¯ãªãæ£è
ã蚺å¯ããŠããäžã§åé¡ãšãªãé
ç®ã®ãªã¹ãã§ããïŒåŸã£ãŠãå蚺æã«åŸããããå蚺ã§ã®åé¡ç¹ãèšåºçç¶ãèšºå¯æèŠãæ€æ»å€ã®ç°åžžãªã©ãããªã¹ãã¢ãããããã¹ããã®ã§ããïŒå
¥é¢åŸçµéïŒå€æ¥èšºçäžã®çµéïŒãšèå¯ç¹æ®æ€æ»çãå«ã蚺æãšãã®æ ¹æ ãæ²»çãšãã®ãšããã³ã¹ããã³è»¢åž°ã«ã€ããŠèšèŒããïŒèå¯ã¯äž»ç
åãäžå¿ã«ãã®éç床ã蚺æããã³æ²»çæ³éžæã«ãããåŠ¥åœæ§ãç°¡æœã«è°è«ããïŒâ»ãå
¥é¢åŸçµéããšãèå¯ãã¯ããããããããã¬ã ãç
忝ã«ç¬ç«ããŠèšèŒãããããããã¯äœµããŠèšèŒãããããããã®æ§åŒã§ãæ§ããªãïŒâ» å€ç§ç޹ä»çäŸã«ã€ããŠã¯æè¡æèŠãå«ããŠèå¯ããããšïŒãŸãã忀çäŸã«ã€ããŠã¯åæ€æèŠãå«ããŠèå¯ããããšç·åèå¯ãäž»ç
åãäžå¿ã«ãã®éç床ãå¯ç
åãšã®é¢é£ã«ã€ããŠèšå蚺æããã»ã¹ã¯é©åã çŸç
æŽã«é¢ããèŽåã¯é°æ§æèŠãå«ããŠååèšèŒãããŠãããïŒ çµéïŒèº«äœèšºå¯ã®èšèŒã¯å
åã§ãããïŒ èšºæã«å¿
èŠãªæ€æ»ã®èšèŒã¯å
åã§ãããïŒ èšºæã«å¿
èŠãªç»åæèŠã®èšèŒã¯å
åã§ããã éå¥èšºæã«ã€ããŠã¯ååèšèŒãããŠããã æ²»çæ³ã¯é©åãäž»ç
åã®æ²»çã«ã€ããŠèšèŒãå
åã§ãããïŒ å«ççåŠ¥åœæ§ïŒå«ççé
æ
®ïŒæ£è
ãå
šäººçèŠéã§èšºçããŠãããïŒãçŸç
æŽããæ¢åŸæŽããå®¶ææŽããçæŽ»æŽããäž»ãªå
¥é¢æçŸçããäž»èŠãªæ€æ»æèŠãããããã¬ã ãªã¹ãããå
¥é¢åŸçµéãšèå¯ããå
¥åããã®ã§å
ç§ãµããªãŒã宿ãããŠäžãããç¶ããŠãçäŸãå ¥å
ä»åã¯ç
æŽèŠçŽã®äŸãçšããŠããŸããã
å人æ
å ±éšåã¯ããããªãããã«ããŠãã ãããæ¥æã¯æããŠããã®ãè¯ãã§ãããã
ç
æŽèŠçŽã®æªãäŸãå
¥åããŸã
ãäž»èšŽã æ¯åãã»é£æ¬²äžæ¯ïŒ
ãçŸç
æŽã
å¹³æ28幎4æïŒäž¡äžè¢çããã³å
šèº«åŠæ æãåºçŸïŒ5æäžæ¬é ããïŒæ¯åããåºçŸïŒ6æ
äžæ¬ïŒå³åœã䌎ãããã«ãªãïŒ7æ2æ¥âÃå»é¢ã«ãŠå蚺ïŒèžéšXç·åçã§èºãã£è¡ãèª
ãïŒå¿äžå
šã®èšºæã§7æ4æ¥åœç§ç޹ä»å
¥é¢ãšãªã£ãïŒ
ãæ¢åŸæŽã 30æ³ïŒè朰ç
ãå®¶ææŽã ç¶ïŒèç
ãçæŽ»æŽã å«ç
ïŒ30ã50æ¬/æ¥ïŒã¢ã«ã³ãŒã«ïŒããŒã« 1ã2æ¬/æ¥ïŒ
ãäž»ãªå
¥é¢æçŸçã
èº«é· 164 cmïŒäœé 62 kgïŒäœæž© 36.9âïŒBP 88/58 mmHgïŒèžçŒçŒçµèã«è²§è¡ãªãïŒçŒ
ççµèã«é»çžãªãïŒå¿é³ïŒâ
ïŒâ
¡é³ã¯æž
ïŒå¿å°éšåçž®æéé³ïŒLevineâ
¢/â
¥ïŒïŒäž¡èºéïŒæ¹¿
æ§ã©é³ãèŽå.
ãäž»èŠãªæ€æ»æèŠã BNP 650 pg/mL
ïŒåèè¡ã¬ã¹åæïŒPHïŒ7.484ïŒPaCO2ïŒ34TorrïŒPaO2ïŒ99.1TorrïŒHCO3âïŒ25.3 mEq/LïŒ
SatO2ïŒ98.0%ïŒ
èžéšXpïŒå¿æ¡å€§ïŒCTR 58%ïŒïŒèºãã£è¡ïŒäž¡åŽèžæ°Ž
å®éæå¿é»å³ïŒå¿æ¿çްå
ïŒãã«ã¿ãŒå¿é»å³ïŒç·å¿ææ° 111,730/24hrsïŒå¿æ¿çްå
ãå¹³åå¿ææ° 77/åïŒæé«107/æäœ51ïŒ
ãå¿å®€æ§æå€åçž®ïŒ3,480åïŒæå€§7é£çºã®å¿å®€é »æããããã¬ã ãªã¹ãã
ã#1ïŒãã£è¡æ§å¿äžå
š
ã#2ïŒå§åžœåŒééäžå
š
ã#3ïŒå¿æ¿çްå
ã#4ïŒå¿å®€é »æç
ãå
¥é¢åŸçµéãšèå¯ã
#1ïŒãã£è¡æ§å¿äžå
šã¯ïŒé
žçŽ æäžããã³ããã»ããéæ³šã«ããå©å°¿å¹æãåŸããïŒéã
ãã«æ¹åããïŒå¿äžå
šã®åå ã¯ïŒå¿èã«ããŒãã«æ€æ»ã§å åèç
å€ã¯èªããïŒå·Šå®€å
šåšæ§
ã«å£éåäœäžãèªããããšããïŒå¿ççŸæ£ãèããããïŒå·Šå®€å¿ççæ€ã§ïŒå¿ç现èã®å€
æ§æèŠãèªãããïŒæ¡åŒµåå¿ççãšèšºæããïŒå
æçæ³ã¯ïŒã«ãŒãããã³æã¢ã«ãã¹ãã
ã³æ§å©å°¿è¬ïŒACEé»å®³è¬ããã³Î²é®æè¬ã®äœµçšçæ³ãéå§ããïŒ
#2ïŒ#3ïŒãŸãå§åžœåŒééäžå
šã¯ïŒå¿äžå
šæ¹ååŸã«ã¯â
¡åºŠãŸã§ã«æ¹åããã®ã§ïŒåœé¢ä¿å
çã«çµé芳å¯ããããšãšããïŒå¿æ¿çްåã«é¢ããŠã¯ïŒé»æ°çé€çްåã詊ã¿äžæŠã¯é€çްåã
ãããïŒæŽèª¿åŸãç¶æã§ããïŒå¿ææ°ã³ã³ãããŒã«ãšè¡æ 塿 äºé²çæ³ãäž»ã«å
ææ²»çã
éå§ããïŒ
#4ïŒå¿å®€é »æçVTã¯éæç¶æ§ã§ãã£ããïŒå·Šå®€åçž®äžå
šäŸã§ããïŒæ©éã¢ããªããã³ã®
æäžãéå§ããïŒæäžåŸããã¯3é£ä»¥äžã®å¿å®€é »æã¯èªããããïŒé»æ°ççåŠçæ€æ»ã§ã®
VTèªçºåºæ¿è©Šéšã«ãŠãïŒVTåºçŸããªãããšã確èªããïŒä»åŸã¯åã蟌ã¿åé€çްååšã®
é©å¿ã®æ€èšãå¿
èŠãšæãããïŒçµæ
ã䞻蚎ã
æ¯åããšé£æ¬²äžæ¯
ãçŸç
æŽã
å¹³æ28幎4æïŒäž¡äžè¢çãšå
šèº«åŠæ æåºçŸ
5æäžæ¬ïŒæ¯åãåºçŸ
6æäžæ¬ïŒå³åœã䌎ãããã«ãªã
7æ2æ¥ïŒèžéšXç·åçã§èºãã£è¡ãèªãïŒå¿äžå
šãšèšºæããã
7æ4æ¥ïŒåœç§ç޹ä»å
¥é¢
ãæ¢åŸæŽã
èæœ°çïŒ30æ³ïŒ
ãå®¶ææŽã
ç¶ïŒèç
ãçæŽ»æŽã
å«ç
ïŒ30ã50æ¬/æ¥
ã¢ã«ã³ãŒã«ïŒããŒã« 1ã2æ¬/æ¥
ãäž»ãªå
¥é¢æçŸçã
èº«é· 164 cmïŒäœé 62 kgïŒäœæž© 36.9âïŒBP 88/58 mmHgïŒ
èžçŒçŒçµèã«è²§è¡ãªãïŒçŒççµèã«é»çžãªãïŒ
å¿é³ïŒâ
ïŒâ
¡é³ã¯æž
ïŒå¿å°éšåçž®æéé³ïŒLevineâ
¢/â
¥ïŒïŒ
äž¡èºéïŒæ¹¿æ§ã©é³ãèŽåïŒ
ãäž»èŠãªæ€æ»æèŠã
BNP 650 pg/mL
åèè¡ã¬ã¹åæïŒ
PHïŒ7.484ïŒPaCO2ïŒ34TorrïŒPaO2ïŒ99.1TorrïŒHCO3âïŒ25.3 mEq/LïŒSatO2ïŒ98.0%ïŒ
èžéšXpïŒå¿æ¡å€§ïŒCTR 58%ïŒïŒèºãã£è¡ïŒäž¡åŽèžæ°Ž
å®éæå¿é»å³ïŒå¿æ¿çްå
ãã«ã¿ãŒå¿é»å³ïŒ
ç·å¿ææ° 111,730/24hrsïŒå¿æ¿çްå
å¹³åå¿ææ° 77/åïŒæé«107/æäœ51ïŒ
å¿å®€æ§æå€åçž®ïŒ3,480åïŒæå€§7é£çºã®å¿å®€é »æ
ããããã¬ã ãªã¹ãã
#1. ãã£è¡æ§å¿äžå
š
#2. å§åžœåŒééäžå
š
#3. å¿æ¿çްå
#4. å¿å®€é »æç
ãå
¥é¢åŸçµéãšèå¯ã
#1. ãã£è¡æ§å¿äžå
šã«ã€ããŠã¯ãé
žçŽ æäžãšããã»ããéæ³šã«ããå©å°¿å¹æã«ããéããã«æ¹åãèŠãããŸãããå¿äžå
šã®åå ã¯ãå¿èã«ããŒãã«æ€æ»ã§å åèç
å€ã¯èªããããã巊宀å
šåšæ§ã«å£éåäœäžãèªããããããšãããå¿ççŸæ£ãçãããŸããã巊宀å¿ççæ€ã§å¿ç现èã®å€æ§æèŠãèªããããæ¡åŒµåå¿ççãšèšºæãããŸãããå
æçæ³ãšããŠãã«ãŒãããã³æã¢ã«ãã¹ããã³æ§å©å°¿è¬ãACEé»å®³è¬ããã³Î²é®æè¬ã®äœµçšçæ³ãéå§ããçç¶ã®æ¹åãèŠãããŠããŸãã
#2. å§åžœåŒééäžå
šã«ã€ããŠã¯ãå¿äžå
šæ¹ååŸã«ã¯â
¡åºŠãŸã§ã«æ¹åããä¿åçã«çµé芳å¯ããããšãšããŸããã
#3. å¿æ¿çްåã«ã€ããŠã¯ã黿°çé€çްåã詊ã¿äžæŠã¯é€çްåãããããæŽèª¿åŸãç¶æã§ãããå¿ææ°ã³ã³ãããŒã«ãšè¡æ 塿 äºé²çæ³ãäž»ã«å
ææ²»çãéå§ããŸããã
#4. å¿å®€é »æçVTã«ã€ããŠã¯ã巊宀åçž®äžå
šäŸã§ãããã¢ããªããã³ã®æäžã«ããå¿å®€é »æã®æ¹åãèŠãããVTèªçºåºæ¿è©Šéšã«ãŠãVTåºçŸããªãããšã確èªãããŸãããä»åŸã¯åã蟌ã¿åé€çްååšã®é©å¿ã®æ€èšãå¿
èŠãšãããŠããŸãã
ãç·åèå¯ã
æ¬æ£è
ã¯ã巊宀æ¡åŒµåå¿ççã«ãããã£è¡æ§å¿äžå
šãäž»ç
åãšããå§åžœåŒééäžå
šãå¿æ¿çްåãå¿å®€é »æçã䜵çºããŠãããå¿èã«ããŒãã«æ€æ»ã§å åèç
å€ã¯èªããããã巊宀å
šåšæ§ã«å£éåäœäžãèªããããšãããå¿ççŸæ£ãçããã巊宀å¿ççæ€ã§æ¡åŒµåå¿ççã確å®èšºæããããæ²»çãšããŠã¯ãã«ãŒãããã³æã¢ã«ãã¹ããã³æ§å©å°¿è¬ãACEé»å®³è¬ããã³Î²é®æè¬ã®äœµçšçæ³ãéå§ãããã
ãŸããå¿æ¿çްåã«é¢ããŠã¯ã黿°çé€çްåã詊ã¿ãããæŽèª¿åŸãç¶æã§ãããå¿ææ°ã³ã³ãããŒã«ãšè¡æ 塿 äºé²çæ³ãäž»ã«å
ææ²»çãéå§ãããããã«ãå¿å®€é »æçã«å¯ŸããŠã¯ãã¢ããªããã³ã®æäžã«ããå¿å®€é »æã¯æ¹åãããã
ä»åŸã¯ã宿çãªå¿èæ€æ»ãè¡ããåã蟌ã¿åé€çްååšã®é©å¿ã®æ€èšãå¿
èŠã§ããããŸããçŠç
ããã³æžé
ã®æå°ãå¿
èŠã§ãããããŠãè¯ããµããªäŸãšæ¯èŒãããšChatGPTãäœã£ãŠããããµããªãŒã§ãã以äžã®çç±ã§ãã¡ã§ãã
å¿äžå šäºæ ã®è©äŸ¡ãçã
蚺æãšæ²»çæ ¹æ ã«ä¹ãã
ãã®ãããé
ç®ãè¶³ããªãå ŽåãµããªãŒèªäœèŠããã§ãã
æ¹åã«ã€ããŠã¯ãããããªæ¹æ³ããããŸãã
æ¹åããã³ãã
çŸåšã®ãµããªã§ã¯å°éå»è©Šéšã«ã¯äžåæ ŒãšãªãããšãããããŸããã蚺æãšæ²»çæ ¹æ ãä¹ããããã§ããæ¹åãã€ã³ãããããŠäžããããããã詊ããŸãããããããæ¹åã«ã¯ããã£ãã§ã
çŸåšã®ãµããªãŒã«ãããŠã以äžã®ç¹ãæ¹åã®å¿
èŠããããŸãã
蚺æãšæ²»çæ ¹æ ã®äžè¶³
ãµããªãŒã«ã¯èšºæãæ²»çã®æ ¹æ ãæç¢ºã«ç€ºãããŠããããå°éå»è©Šéšã§äžåæ Œãšãããçç±ãšãªããŸããæ€æ»ãæ²»çæ³ã«ã€ããŠããã詳现ãªèª¬æãæ ¹æ ã瀺ãããšãæ±ããããŸãã
ãããã¬ã ãªã¹ãã®æŽç
ãããã¬ã ãªã¹ãã¯ã蚺æãæ²»çã«é¢ããåé¡ç¹ãæŽçããããã®ãã®ã§ãããå¿
èŠæå°éã®ãããã¬ã ãåæããããšãæãŸããã§ããçŸåšã®ãµããªãŒã«ã¯ãå¿
èŠä»¥äžã«å€ãã®ãããã¬ã ãåæãããŠãããæŽçããããšãæ±ããããŸãã
å
¥é¢åŸçµéãšèå¯ã®äžè¶³
çŸåšã®ãµããªãŒã«ã¯ãå
¥é¢åŸã®æ²»ççµéãæ²»çæ¹éã«å¯Ÿããèå¯ãäžååã§ããæ²»çã®çµéãèå¯ã«ã€ããŠããã詳现ã«èšè¿°ããããšãæ±ããããŸãã
æ£è
ã®èæ¯æ
å ±ã®äžè¶³
æ£è
ã®èæ¯æ
å ±ïŒæ¢åŸæŽãå®¶ææŽãçæŽ»æŽçïŒã«ã€ããŠããã詳现ã«èšè¿°ããããšãæ±ããããŸãããããã®æ
å ±ã¯ã蚺æãæ²»çã®å€æã«å€§ããªåœ±é¿ãäžããããšããããããéèŠãªæ
å ±ãé©åã«èšèŒããããšãå¿
èŠã§ãã
è¡šçŸæ¹æ³ã®çµ±äžæ§
çŸåšã®ãµããªãŒã«ã¯ãè¡šçŸæ¹æ³ãçµ±äžãããŠããªãç®æããããŸããæ°å€ã®åäœããæ€æ»çµæã®èšèŒæ¹æ³ãªã©ãè¡šçŸæ¹æ³ãçµ±äžããããšãå¿
èŠã§ãããŸããç¥èªã®äœ¿çšãé¿ããå°éçšèªãé©åã«äœ¿çšããããšãéèŠã§ãããã®æ¹åãã€ã³ããåæ ããŠãã ãããšãããšè¯ããªããŸããããµããªã®å
容ãåé¡ã«ãªã£ãŠããã®ã§ãµããªã¯æ¹åããŸããã§ããã
çµè«ãšããŠããµããªã®è¶³ããªãé
ç®ãçŽããŠããäœæ¥ãå¿
èŠã«ãªããŸãã
GPT-4ãæå ¥
ææã®GPT-4ã§è©ŠããŠã¿ãŸãã䌌ããå¯ã£ããã§ãããæ¹åãã€ã³ãã®ææã¯3.5ãããããããŠããŸããã
å°éå»ã®ãµããªãŒãšããŠãæ¹åãã€ã³ãããããŠäžããã
å°éå»ã®ãµããªãŒãšããŠã以äžã®æ¹åãã€ã³ããæããŸãã
çŸç
æŽã®èšèŒ:
çŸç
æŽã®èŽåã«ãããŠãé°æ§æèŠãå«ããŠè©³çŽ°ãªæ
å ±ãåéããããç¶¿å¯ãªèšèŒãè¡ãããšãæãŸããã§ãã
éå¥èšºæã®å±é:
éå¥èšºæã«ã€ããŠãããã«å¹
åºãå¯èœæ§ãæ€èšããããããã®çŸæ£ã«å¯Ÿããæ€æ»ãæ²»çã®éžæè¢ãèæ
®ããããšãéèŠã§ãã
æ²»çæ¹éã®èª¬æ:
æ²»çæ³ãé©åã§ããçç±ãããå
·äœçã«èª¬æããæ£è
ãå®¶æã«å¯ŸããŠãçè§£ãããã圢ã§äŒããããšãæãŸããã§ãã
ãšããã³ã¹ã«åºã¥ããæ²»çéžæ:
æ²»çæ³éžæã«ãããŠãææ°ã®ãšããã³ã¹ãã¬ã€ãã©ã€ã³ãåç
§ããæé©ãªæ²»çæ³ãéžæããããšãéèŠã§ãã
ãã©ããŒã¢ããèšç»ã®æç¢ºå:
æ£è
ã®ä»åŸã®ãã©ããŒã¢ããèšç»ãæç¢ºã«èšèŒããé©åãªæ²»çãæ€æ»ã®å®æœã確å®ã«è¡ãããšãå¿
èŠã§ãã
æ£è
ãšã®ã³ãã¥ãã±ãŒã·ã§ã³:
æ£è
ãšã®ã³ãã¥ãã±ãŒã·ã§ã³ãéèŠããæ£è
ã®æèŠãåžæãæ²»çèšç»ã«åæ ãããããšã倧åã§ãã
ç·åçãªã¢ãããŒã:
ç
æ
ã®ææ¡ãæ²»çæ¹éã®æ±ºå®ã«ãããŠãæ£è
ã®å
šäººçèŠéãèæ
®ããç·åçãªã¢ãããŒããéèŠã§ãã
ãããã®æ¹åãã€ã³ããèžãŸããŠããã質ã®é«ããµããªãŒäœæãç®æãããšãæ±ããããŸããGPT3.5 x English
GPTãšããã°è±èªã§äœ¿çšãããšæ§èœãäžãããŸãã
Please help me prepare an internal medicine summary for senior doctor. The rules are as follows: - Prepare a POS (Problem Oriented System) summary of the patient's medical history. Do not use abbreviations for the definitive diagnosis of hernia of foramen magnum that can be recalled from the symptoms and paroxysmal hip pain. The main disease should be listed as 1, according to the severity and importance of the patient's hospitalization (or outpatient hospitalization). List the secondary illnesses and complications below 2. List the main illnesses. Briefly mention the history of all other major and secondary illnesses and complications. It is not necessary to give a complete history of previous illnesses, family history, and life history. Profile and occupation should be included if important. âPresent symptoms at admission (present symptoms at outpatient consultation): Reduce unnecessary information and summarize to the point. Problem listProblems listed in the problem list are not diagnostic names, but a list of items that may be problematic in the course of examining the patient. Therefore, they should be listed based on the problems, clinical symptoms, examination findings, and abnormal laboratory values obtained at the time of the initial visit. The course of the patient after admission (during outpatient care) and discussionThe diagnosis and its rationale, including special tests, and the treatment, its evidence, and outcome should be described. The discussion should focus on the main disease and briefly discuss its severity, diagnosis, and appropriateness in the selection of treatment. The "Progress after admission" and "Discussion" can be written independently for each problem or disease, or they can be written together. For cases referred to the Department of Surgery, surgical findings should be included in the discussion. The diagnosis process should be described with reference to the severity of the main disease and its relationship to the secondary diseases. Is the history and physical examination adequately described? Is the description of the examination necessary for the diagnosis sufficient? Is the differential diagnosis adequately described? Is the treatment method appropriate and is the treatment of the main disease adequately described? Please complete the Internal Medicine Summary by entering the following information: [Current Medical History], [Previous Medical History], [Family History], [Life History], [Major Present Illnesses on Admission], [Major Laboratory Findings], [Problem List], and [Post-admission Progress and Discussion].å ¥å
DeepLã«æ¥æ¬èªãçªã£èŸŒãã ãã§ãè±èš³ã«ãªããŸãã
Confirmed diagnoses (primary and secondary disease)
Congestive heart failure
#2. dilated cardiomyopathy
#3. atrial fibrillation
#Ventricular tachycardia
Shortness of breath and anorexia.
Current medical history
In April 2008, pain in both lower limbs and general malaise appeared.
In mid-June, he began coughing, and was examined at XXX clinic on July 2. A chest X-ray showed pulmonary congestion.
He was admitted to our hospital on July 4 with a diagnosis of heart failure.
Family history] 30 years old: gastric ulcer
Family history] Father: gastric cancer
Smoking: 30-50 cigarettes/day, Alcohol: 1-2 beers/day.
Main symptoms at the time of admission
Height 164 cm, weight 62 kg, body temperature 36.9°C, BP 88/58 mmHg, no anemia in thoracic eyelid conjunctiva, no jaundice in ocular conjunctiva.
No anemia in thoracic eyelid conjunctiva, no jaundice in ocular conjunctiva. Heart sounds: I and II clear, apex systolic murmur (Levine III/â
¥). Both lung fields: wet La sound heard.
Both lungs: Wet La sound was heard.
BNP 650 pg/mL.
ïŒArterial blood gas analysis: PH: 7.484, PaCO2: 34 Torr, PaO2: 99.1 Torr, HCO3-: 25.3 mEq/L, SatO2: 98.0%.
SatO2: 98.0%.
Chest Xp: enlarged heart (CTR 58%), pulmonary congestion, bilateral pleural effusion.
Resting ECG: atrial fibrillation
ïŒTotal heart rate 111,730/24hrs, atrial fibrillation
ãMean heart rate 77/min (max 107/min 51)
ãVentricular extrasystoles: 3,480, max 7 consecutive ventricular tachycardia [Problem list] #1.
ã#1. congestive heart failure
ã#2. mitral regurgitation
ã#3. atrial fibrillation
ã#4. ventricular tachycardia
Post-hospitalization course and discussion
#1. Congestive heart failure was quickly improved by oxygenation and diuretic effect of intravenous furosemide.
The cause of the heart failure was a cardiac catheterization. The cause of the heart failure was due to the fact that cardiac catheterization revealed no coronary artery lesions and left ventricular circumferential hypokinesia.
The cause of heart failure was considered to be myocardial disease. A biopsy of the left ventricular myocardium showed evidence of myocyte degeneration.
A left ventricular myocardial biopsy showed evidence of myocyte degeneration, and a diagnosis of dilated cardiomyopathy was made. The patient was treated with loop and anti-aldosterone diuretics, ACE
The patient was started on a combination of loop and anti-aldosteron diuretics, ACE inhibitors, and beta-blockers.
#The patient's mitral regurgitation improved to grade II after improvement of heart failure, and he was followed conservatively for the time being.
The patient was followed up conservatively for the time being. The patient was defibrillated by electrical cardioversion, but was unable to maintain sinus rhythm.
The patient was started on medical therapy mainly for heart rate control and thromboembolic prophylaxis.
The patient was started on medical therapy mainly for heart rate control and thromboembolic prophylaxis.
#The patient was started on medical therapy mainly for rate control and thromboembolic prophylaxis. 4.
The patient was started on amiodarone immediately. After administration, no more than three series of ventricular tachycardia were observed, and the VT-evoked stimulation test on electrophysiological examination was also performed.
The patient did not have any VT in the VT-evoked stimulation test. In the future, it is necessary to consider the indication for implantable cardioverter defibrillator.
The indication of implantable cardioverter defibrillator should be considered in the future.çµæ
Confirmed diagnoses:
Congestive heart failure
Dilated cardiomyopathy
Atrial fibrillation
Ventricular tachycardia
Current medical history:
In April 2008, the patient experienced pain in both lower limbs and general malaise. In mid-June, he began coughing and was diagnosed with pulmonary congestion via chest X-ray at XXX clinic on July 2. The patient was admitted to the hospital on July 4 with a diagnosis of heart failure. The patient has a history of heavy smoking (30-50 cigarettes/day) and alcohol consumption (1-2 beers/day).
Family history:
The patient's younger sibling had gastric ulcer at the age of 30. The patient's father had gastric cancer.
Main symptoms at the time of admission:
The patient had a height of 164 cm, weight of 62 kg, body temperature of 36.9°C, and BP of 88/58 mmHg. Heart sounds I and II were clear, and an apex systolic murmur (Levine III/â
¥) was heard. Wet La sound was heard in both lung fields. The patient had a BNP of 650 pg/mL, and a chest X-ray showed an enlarged heart (CTR 58%), pulmonary congestion, and bilateral pleural effusion. The patient was also diagnosed with atrial fibrillation via resting ECG.
Problem list:
Congestive heart failure
Mitral regurgitation
Atrial fibrillation
Ventricular tachycardia
Post-hospitalization course and discussion:
The patient's congestive heart failure was quickly improved by oxygenation and diuretic effect of intravenous furosemide. The cause of the heart failure was determined to be due to left ventricular circumferential hypokinesia, which was diagnosed as dilated cardiomyopathy via a left ventricular myocardial biopsy. The patient was started on a combination of loop and anti-aldosterone diuretics, ACE inhibitors, and beta-blockers. The patient's mitral regurgitation improved to grade II after improvement of heart failure, and was followed conservatively for the time being. The patient was started on medical therapy mainly for heart rate control and thromboembolic prophylaxis for atrial fibrillation. The patient was also started on amiodarone for ventricular tachycardia and had no VT in the VT-evoked stimulation test. The indication of implantable cardioverter defibrillator should be considered in the future.
In summary, the patient has a confirmed diagnosis of congestive heart failure, dilated cardiomyopathy, atrial fibrillation, and ventricular tachycardia. The patient's congestive heart failure and atrial fibrillation were managed with diuretics and medical therapy for rate control and thromboembolic prophylaxis. The patient was also started on amiodarone for ventricular tachycardia and will be considered for implantable cardioverter defibrillator in the future.çµè«ããèšããšããããèšºææ ¹æ ãçããèããµããªãŒã«ãªã£ãŠããŸãã
ããããåæ Œã¬ãã«ã«ã¯ãããŸããã
è¯ããµããªãŒãããšãã»ã³ã¹ãæœåºãã
è¯ããµããªãŒãšæªããµããªãŒãæ¯èŒããŠãæªããµããªãŒã«å¿ èŠãªãã€ã³ãããããŠããããŸããã
䞻蚎ãçŸç
æŽãæ¢åŸæŽãå®¶ææŽãçæŽ»æŽãäž»ãªå
¥é¢æçŸçãäž»èŠãªæ€æ»æèŠããããã¬ã ãªã¹ããæç¢ºã«èšèŒããã
æ£è ã®èšºæãæ²»çæ¹éãæç¢ºã«è¿°ã¹ãã
æ²»ç广ãçµé芳å¯ã®çµæãèšèŒããã
æ²»çæ¹éã«ã€ããŠä»åŸã®æ€èšäºé ã瀺ãã
é©åãªææ³ã衚çŸãçšããã
ãããããšã«ãµããªãŒãçŽãããšããŠããChatGPTèªäœã®å»åŠç¥èãè¶³ããªããããµããªã¯æ¹åããŸããã§ããã
é ç®ã远å ããŠåãã©ã€
æå°å»ã«çŽããŠããã£ããšããèšå®ã§ã以äžã远å ããŠã¿ãŸãã
以äžã®æ
å ±ã远å ããŠãµããªãæ¹åãããŠäžããããçŸç
æŽ:ããããŸã§ã«å®æå¥èšºçã«ãããŠå¿çŸæ£ãææãããäºã¯ãªãã£ãïŒåŽäœæã®æ¯åããåºçŸãå€éã®å³åœãå®¶ææŽ:å¿çŸæ£ã®å®¶ææŽã¯ãããŸãããäž»èŠãªæ€æ»æèŠ:ãïŒå¿ãšã³ãŒå³ïŒãå·Šå®€ã®æ¡å€§ãšã³ãŸãæ§ã®å£éåäœäžãèªããïŒLVDd 66 mmïŒLVDs 57
mmïŒIVS 9 mmïŒ LVPW 10 mmïŒLVEF 29ïŒ
ïŒLAD 49 mmïŒMRäžç床ïŒEROïŒ0.15ïŒïŒ
æšå®PAåçž®æå§ 30 mmHgãå
¥é¢åŸçµéãšèå¯:#1ãå
¥é¢æã«ã¯NYHA â
¢åºŠãèè¡æ§å¿ççã¯åŠå®
ãããŠå¿ççŸæ£ãèããããïŒ ãŸãïŒé«è¡å§ã®æ¢åŸããªãïŒæ¯å¹Žã®å¥èšºã§ã匷ãå¿éé³ã
ææãããŠããªãäºããïŒé«è¡å§æ§å¿èç
ãäžæ¬¡æ§ã®åŒèçã®å¯èœæ§ã¯äœãïŒããã«ïŒå³
宀å¿ççæ€ã§ïŒå¿ç现èã®å€æ§æèŠãèªããããäžæ¹ã§ïŒã¢ããã€ãæ²çããµã«ã³ã€ã
çµç¯ããã³çççŽ°èæµžæœ€ãªã©ãèªããããªãããšãã æ¡åŒµåå¿ççãšèšºæããïŒRoberts
WC. Am J Cardiol 1989;63:893ïŒïŒãªãïŒç
ç¶ãå®å®ããŠãã宿œããå³å¿ã«ããŒãã«æ€
æ»ã§ã¯èºåèæ¥å
¥å§ 16 mmHgïŒå¿ä¿æ° 2.8 L/min/m2ã§ãã£ãïŒã«ã«ããžããŒã«ã¯2.5 mgããéå§ãïŒç
ç¶ã®æªåã®ãªãäºã確èªããŠ5 mgãŸã§å¢
éããŠãããïŒè¡å§ã¯90/60 mmHgãšå
¥é¢æããæãããªäœäžã¯ãªãïŒé颿ã®äœéã
59 kgã§ãã£ãïŒçµæã¯ãChatGPTã§ã¯éåããã¡ãªã®ã§ãé©å®ç¶ããŠãªã©ãšå
¥åããå¿
èŠããããŸããäœã£ãŠãããŸã
ãäž»èšŽã æ¯åãã»é£æ¬²äžæ¯ïŒ
ãçŸç
æŽã
å¹³æ28幎4æïŒäž¡äžè¢çããã³å
šèº«åŠæ æãåºçŸïŒ5æäžæ¬é ããïŒåŽäœæã®æ¯åããåºçŸãå€éã®å³åœãããã6æäžæ¬ãå³åœã䌎ãããã«ãªãã7æ2æ¥âÃå»é¢ã«ãŠå蚺ãèžéšXç·åçã§èºãã£è¡ãèªããå¿äžå
šã®èšºæã§7æ4æ¥åœç§ç޹ä»å
¥é¢ãšãªã£ãã
ãæ¢åŸæŽã 30æ³ïŒè朰ç
ãå®¶ææŽã å¿çŸæ£ã®å®¶ææŽã¯ãããŸãã
ãçæŽ»æŽã å«ç
ïŒ30ã50æ¬/æ¥ïŒã¢ã«ã³ãŒã«ïŒããŒã« 1ã2æ¬/æ¥ïŒ
ãäž»ãªå
¥é¢æçŸçã
èº«é· 164 cmïŒäœé 62 kgïŒäœæž© 36.9âïŒBP 88/58 mmHgïŒèžçŒçŒçµèã«è²§è¡ãªãïŒçŒ
ççµèã«é»çžãªãïŒå¿é³ïŒâ
ïŒâ
¡é³ã¯æž
ïŒå¿å°éšåçž®æéé³ïŒLevineâ
¢/â
¥ïŒïŒäž¡èºéïŒæ¹¿
æ§ã©é³ãèŽå.
ãäž»èŠãªæ€æ»æèŠã BNP 650 pg/mL
ïŒåèè¡ã¬ã¹åæïŒPHïŒ7.484ïŒPaCO2ïŒ34TorrïŒPaO2ïŒ99.1TorrïŒHCO3âïŒ25.3 mEq/LïŒ
SatO2ïŒ98.0%ïŒ
ïŒå¿ãšã³ãŒå³ïŒå·Šå®€ã®æ¡å€§ãšã³ãŸãæ§ã®å£éåäœäžãèªããïŒLVDd 66 mmïŒLVDs 57
mmïŒIVS 9 mmïŒ LVPW 10 mmïŒLVEF 29ïŒ
ïŒLAD 49 mmïŒMRäžç床ïŒEROïŒ0.15ïŒïŒ
æšå®PAåçž®æå§ 30 mmHg
èžéšXpïŒå¿æ¡å€§ïŒCTR 58%ïŒïŒèºãã£è¡ïŒäž¡åŽèžæ°Ž
å®éæå¿é»å³ïŒå¿æ¿çްå
ïŒãã«ã¿ãŒå¿é»å³ïŒç·å¿ææ° 111,730/24hrsïŒå¿æ¿çްå
ãå¹³åå¿ææ° 77/åïŒæé«107/æäœ51ïŒ
ãå¿å®€æ§æå€åçž®ïŒ3,480åïŒæå€§7é£çºã®å¿å®€é »æ
#1 ãã£è¡æ§å¿äžå
šã¯ãé
žçŽ æäžããã³ããã»ããéæ³šã«ããå©å°¿å¹æãåŸãããéããã«æ¹åãããå¿äžå
šã®åå ã¯ã巊宀å
šåšæ§ã«å£éåäœäžãèªããããšãããå¿ççŸæ£ãèãããããå¿èã«ããŒãã«æ€æ»ã§ã¯å åèç
å€ã¯èªããã巊宀å¿ççæ€ã§æ¡åŒµåå¿ççãšèšºæãããå
æçæ³ã¯ãã«ãŒãããã³æã¢ã«ãã¹ããã³æ§å©å°¿è¬ãACEé»å®³è¬ããã³Î²é®æè¬ã®äœµçšçæ³ãéå§ããã
#2, #3 å§åžœåŒééäžå
šã¯ãå¿äžå
šæ¹ååŸã«ã¯â
¡åºŠãŸã§ã«æ¹åããã®ã§ãåœé¢ä¿åçã«çµé芳å¯ããããšãšãããå¿æ¿çްåã«é¢ããŠã¯ã黿°çé€çްåã詊ã¿äžæŠã¯é€çްåãããããæŽèª¿åŸãç¶æã§ãããå¿ææ°ã³ã³ãããŒã«ãšè¡æ 塿 äºé²çæ³ãäž»ã«å
ææ²»çãéå§ããã
#4 å¿å®€é »æçVTã¯éæç¶æ§ã§ãã£ããã巊宀åçž®äžå
šäŸã§ãããã¢ããªããã³ã®æäžãéå§ãããæäžåŸããã¯3é£ä»¥äžã®å¿å®€é »æã¯èªããããã黿°ççåŠçæ€æ»ã§ã®VTèªçºåºæ¿è©Šéšã«ãŠããVTåºçŸããªãããšã確èªãããä»åŸã¯åã蟌ã¿åé€çްååšã®é©å¿ã®æ€èšãå¿
èŠãšæãããã
#5 æ¡åŒµåå¿ççã¯ãå¿äžå
šåå ãšããŠèãããããå³å®€å¿ççæ€ã§ã¯ã¢ããã€ãæ²çããµã«ã³ã€ãçµç¯ããã³çççŽ°èæµžæœ€ãªã©ãèªããããªãã£ããã«ã«ããžããŒã«ã¯ç
ç¶ã®æªåã®ãªãããšã確èªãã2.5 mgãã5 mgãŸã§å¢éãããç
ç¶ã¯å®å®ããŠãããé颿ã®äœéã¯59 kgã§ãã£ãã
ä»åŸã¯çµé芳å¯ãç¶ç¶ããå¿
èŠã«å¿ããŠå
æè¬ã®èª¿æŽãåã蟌ã¿åé€çްååšã®é©å¿ã®æ€èšãè¡ãããšãå¿
èŠã§ããã
ç·åèå¯
ãã®æ£è
ããã¯ãå¿äžå
šãå§åžœåŒééäžå
šãå¿æ¿çްåãå¿å®€é »æçã®èšºæããããæ¡åŒµåå¿ççãçãããããå
¥é¢æ²»çãè¡ããŸãããå¿äžå
šã«å¯ŸããŠã¯ãã«ãŒãããã³æã¢ã«ãã¹ããã³æ§å©å°¿è¬ãACEé»å®³è¬ããã³Î²é®æè¬ã®äœµçšçæ³ãè¡ãããã£è¡æ§å¿äžå
šã¯éããã«æ¹åãããŸãããå§åžœåŒééäžå
šã«é¢ããŠã¯ãä¿åçã«çµé芳å¯ããããšãšããŸãããå¿æ¿çްåã«é¢ããŠã¯ã黿°çé€çްåã詊ã¿ãäžæŠã¯é€çްåãããŸããããæŽèª¿åŸãç¶æã§ãããå¿ææ°ã³ã³ãããŒã«ãšè¡æ 塿 äºé²çæ³ãäž»ã«å
ææ²»çãéå§ããŸãããå¿å®€é »æçã«é¢ããŠã¯ãã¢ããªããã³ã®æäžãéå§ããæäžåŸããã¯3é£ä»¥äžã®å¿å®€é »æã¯èªãããããåã蟌ã¿åé€çްååšã®é©å¿ã®æ€èšãå¿
èŠãšãããŸããã
å
¥é¢åŸã«è¡ãããå¿ãšã³ãŒå³ã§ã¯ãå·Šå®€ã®æ¡å€§ãšã³ãŸãæ§ã®å£éåäœäžãèªããLVDd 66 mmãLVDs 57 mmãIVS 9 mmãLVPW 10 mmãLVEF 29ïŒ
ãLAD 49 mmãMRäžçåºŠãæšå®PAåçž®æå§30 mmHgãèªããããŸãããå³å®€å¿ççæ€ã§ãå¿ç现èã®å€æ§æèŠãèªããããäžæ¹ã§ãã¢ããã€ãæ²çããµã«ã³ã€ãçµç¯ããã³çççŽ°èæµžæœ€ãªã©ãèªãããããæ¡åŒµåå¿ççã蚺æãããŸãããã«ã«ããžããŒã«ã¯2.5 mgããéå§ããç
ç¶ã®æªåã®ãªãããšã確èªããŠ5 mgãŸã§å¢éããŠããŸããããè¡å§ã¯90/60 mmHgãšå
¥é¢æããæãããªäœäžã¯ãªããé颿ã®äœéã59 kgã§ãã£ãã
ç·åçã«èãããšããã®æ£è
ããã¯æ¡åŒµåå¿ççã«ããå¿äžå
šãå¿æ¿çްåãå¿å®€é »æçãå§åžœåŒééäžå
šãæããé«éœ¢ã®ç·æ§ã§ãæ¢åŸæŽã«ãããå°ãšããŠã¯ååã§ã¯ãªãã§ããããïŒããšã¯æç®ããããŠèšãåããªã©ãçµ±äžããã°OKã§ããããChatGPT3.5ãšç¡æã§å¯Ÿå¿å¯èœãªã®ã§å®è·µã¬ãã«ã§è¯ãããã«æããŸããã
æ€èšãçµããŠ
çŸç¶ã§ã¯ãChatGPTãçšããŠå®ç§ãªãµããªãŒãäžçºã§äœæããããšã¯ã§ããŸããã玹ä»ç¶çšåºŠã§ããã°ããããŠããããããªã¯ãªãªãã£ãŒã§ã¯ãããŸãããå°éå»ã§äœ¿çšãããµããªã¬ãã«ã ãšäž»ç åã«å¯ŸããèšèŒãå¿ èŠã§ãã
ç¹ã«ãäž»ç
åã«ç¹åããèšèŒãå¿
èŠã§ãã
ãã®ããã«ãéœæ§ãé°æ§æèŠãçºççµéã墿ªãæ¹åãçµéäžãçµéåŸã®ãã©ããŒã¢ãããæ²»çæ ¹æ ïŒèŠæç®ïŒãå¿
èŠã«ãªããŸãã
éã«èšãã°äž»ç åã«ã€ããŠé ç®ãè¶³ããŠããå Žåã¯ChatGPTã§æç« ã®äœè£ãæŽããããšãå¯èœã§ãã®ã®æ°åã§ãµããªã宿ããŸããäœ¿ãæ¹ã«ã€ããŠã¯ãäžèšãæèããŠã¿ãŠäžãããçäŸã®éžå®ã«ããããäžèšãæèããŠã¿ãŠäžããã
ãµããªãŒã®ã¯ãªãªãã£ãŒãäžããã«ã¯å 容ãè¯ãããå¿ èŠããããŸãã
çµè«
æå°å»ã«åžžæ¥é ããããµããªããã§ãã¯ããŠããããŸãã
ãã®äžããéžå®ããŸããããå
žåçãªã±ãŒã¹ãããã§ãããé£ããã±ãŒã¹ã®å Žåãæ£è§£ãç¡ãå Žåãããã®ã§è©äŸ¡ãå²ããå±éºæ§ããããŸããå®æåºŠã«èªä¿¡ãããã°äœ¿çšããŠè¯ãã§ãããã
ãµããªã®äœè£ãæŽããããæ ¡æ£ã¯GPTã§OKã§ã
ãããã§ããããïŒå®éã¯ãåãæã¡çäŸã®éé¢ãµããªãŒãæå
ã«ããç¶æ³ãªã®ã§ãµããªãŒã倱ç¹ãã«ãã圢ã«å€åœ¢ãããšããã®ããªã¹ã¹ã¡ã§ããååã§ç€ºãããã€ã³ãã¯æå°å»ç®ç·ã®ãšãããªã®ã§ãæäœéã¯ãªã¢ããŠããã°è©äŸ¡ãé«ããªããšæããŸãã